serw-MX  [xml]  
 


    
 DeCS Categories

A08 Nervous System .
A08.186 Central Nervous System .
A08.186.211 Brain .
A08.186.211.132 Brain Stem .
A08.186.211.132.810 Rhombencephalon .
A08.186.211.132.810.591 Myelencephalon .
A08.186.211.132.810.591.500 Medulla Oblongata .
A08.186.211.132.810.591.500.574 Olivary Nucleus .
C04 Neoplasms .
C04.588 Neoplasms by Site .
C04.588.364 Eye Neoplasms .
C04.588.364.818 Retinal Neoplasms .
C11 Eye Diseases .
C11.319 Eye Neoplasms .
C11.319.475 Retinal Neoplasms .
C11.768 Retinal Diseases .
C11.768.717 Retinal Neoplasms .
C11.768.773 Retinitis .
D02 Organic Chemicals .
D02.355 Ethers .
D02.355.601 Methyl Ethers .
D02.355.601.400 Enflurane .
D02.455 Hydrocarbons .
D02.455.326 Hydrocarbons, Acyclic .
D02.455.326.271 Alkenes .
D02.455.326.271.665 Polyenes .
D02.455.326.271.665.202 Carotenoids .
D02.455.326.271.665.202.495 Retinoids .
D02.455.326.271.665.202.495.050 Acitretin .
D02.455.326.271.665.202.495.250 Etretinate .
D02.455.849 Terpenes .
D02.455.849.131 Carotenoids .
D02.455.849.131.495 Retinoids .
D02.455.849.131.495.050 Acitretin .
D02.455.849.131.495.250 Etretinate .
D23 Biological Factors .
D23.767 Pigments, Biological .
D23.767.261 Carotenoids .
D23.767.261.700 Retinoids .
D23.767.261.700.050 Acitretin .
D23.767.261.700.250 Etretinate .
E02 Therapeutics .
E02.760 Patient Care .
E02.760.952 Withholding Treatment .
E05 Investigative Techniques .
E05.318 Epidemiologic Methods .
E05.318.780 Epidemiologic Research Design .
E05.318.780.150 Cross-Over Studies .
H02 Health Occupations .
H02.403 Medicine .
H02.403.220 Community Medicine .
N02 Health Care Facilities, Manpower, and Services .
N02.421 Health Services .
N02.421.585 Patient Care .
N02.421.585.952 Withholding Treatment .
N05 Health Care Quality, Access, and Evaluation .
N05.715 Quality of Health Care .
N05.715.360 Health Care Evaluation Mechanisms .
N05.715.360.780 Epidemiologic Research Design .
N05.715.360.780.150 Cross-Over Studies .
N06 Environment and Public Health .
N06.850 Public Health .
N06.850.520 Epidemiologic Methods .
N06.850.520.445 Epidemiologic Research Design .
N06.850.520.445.150 Cross-Over Studies .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Acitretin .
Acitretin, (Z,E,E,E)-Isomer .
Isoacitretin .
Neotigason .
Ro 10-1670 .
Ro 13-7652 .
Ro-10-1670 .
Ro-13-7652 .
Soriatane .
Ro 101670 .
Ro 137652 .
Ro101670 .
Ro137652 .
Etretin .
Isoetretin .
13-cis-Acitretin .
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. .
1.00
381002
 
Etretinate .
B10-9359 .
Ethyl Etrinoate .
Ro 10-9359 .
Ro-10-9359 .
Tigason .
Tigazon .
B10 9359 .
B109359 .
Etrinoate, Ethyl .
Ro 10 9359 .
Ro 109359 .
Ro109359 .
An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. .
0.49
261336
 
Retinitis .
Neuroretinitis .
Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis). .
0.36
742795
 
Retinal Neoplasms .
Cancer of the Retina .
Cancer, Retinal .
Neoplasms, Retinal .
Retinal Cancer .
Retinal Tumors .
Tumors, Retinal .
Cancers, Retinal .
Neoplasm, Retinal .
Retinal Cancers .
Retinal Neoplasm .
Retinal Tumor .
Tumor, Retinal .
Tumors or cancer of the RETINA. .
0.34
512749
 
Olivary Nucleus .
Basalis, Olivary Nucleus .
Nucleus, Olivary .
Nucleus, Olivary Basal .
Olivary Basal Nucleus .
Basal Nucleus, Olivary .
Nucleus Basalis, Olivary .
A part of the MEDULLA OBLONGATA situated in the olivary body. It is involved with motor control and is a major source of sensory input to the CEREBELLUM. .
0.33
153620
 
Enflurane .
Alyrane .
Enfran .
Enlirane .
Ethrane .
Etran .
An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate. .
0.33
902425
 
Cross-Over Studies .
Cross-Over Design .
Cross-Over Trials .
Crossover Design .
Crossover Studies .
Crossover Trials .
Cross Over Design .
Cross Over Studies .
Cross Over Trials .
Cross-Over Designs .
Cross-Over Study .
Crossover Designs .
Crossover Study .
Design, Cross-Over .
Design, Crossover .
Designs, Cross-Over .
Designs, Crossover .
Studies, Cross-Over .
Studies, Crossover .
Study, Cross-Over .
Study, Crossover .
Trial, Cross-Over .
Trial, Crossover .
Trials, Cross-Over .
Trials, Crossover .
Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) .
0.33
 
Community Medicine .
Medicine, Community .
A branch of medicine concerned with the total health of the individual within the home environment and in the community, and with the application of comprehensive care to the prevention and treatment of illness in the entire community. .
0.33
2891940
 
Withholding Treatment .
Cessation of Treatment .
Withdrawing Treatment .
Care, Withdrawing .
Treatment Cessation .
Treatment Cessations .
Treatment, Withdrawing .
Treatment, Withholding .
Treatments, Withdrawing .
Treatments, Withholding .
Withdrawing Treatments .
Withholding Treatments .
Withdrawing Care .
Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed. .
0.32
6610430